Pancreatitis GLP-1 drugs have been linked to an increased risk of pancreatitis, a potentially life-threatening condition characterized by inflammation of the pancreas
The combined protocol addresses metabolic signaling and energy substrate supply simultaneously
We speculate that this intricate interaction potentially serves as a novel mechanism of fibrosis development, but further explorations using genetic approaches are needed to validate this hypothesis
Originally approved for diabetes management, glucagon-like peptide-1 (GLP-1) receptor agonists like semaglutide have rapidly crossed over into mainstream aesthetic practice by delivering dramatic weight loss in remarkably short time frames
Because semaglutide is once weekly, a shift of even 6 to 8 hours in injection timing creates zero clinical issues
This degree of weight loss in such a large and diverse population suggests that it may be possible to impact the public health burden of multiple obesity-related illnesses. In addition to treating diabetes, semaglutide can now be prescribed for weight management for those with obesity or who are overweight
